Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children
- PMID: 9144122
- DOI: 10.1097/00005176-199704000-00008
Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children
Abstract
Background: Certain strains of lactobacilli may promote recovery from acute diarrhea. Lactobacillus reuteri is of human origin and is a natural colonizer of gastrointestinal tract. In this trial, exogenously administered L. reuteri was studied as a therapeutic agent in acute diarrhea.
Methods: Forty patients between 6 and 36 months of age hospitalized with acute diarrhea (75% rotavirus) were studied. After parental consent, the patients were randomized to one of two treatment groups to receive either 10(10) to 10(11) colony-forming units of L. reuteri or a matching placebo daily for the length of hospitalization or up to 5 days. The clinical outcome of diarrhea and colonization of L. reuteri were evaluated.
Results: The mean (SD) duration of watery diarrhea after treatment was 1.7 (1.6) days in the L. reuteri group and 2.9 (2.3) days in the placebo group (p = 0.07). On the second day of treatment only 26% of patients receiving L. reuteri had watery diarrhea, compared with 81% of those receiving placebo (p = 0.0005). Cultures of lactobacilli from stool samples demonstrated that administration of L. reuteri resulted in colonization of the gastrointestinal tract. Lactobacillus reuteri accounted for > 75% of the total lactobacilli found in children fed with this product.
Conclusions: Lactobacillus reuteri is effective as a therapeutic agent in acute rotavirus diarrhea in children. Further studies are warranted to confirm the present finding and to explore the full therapeutic potential of L. reuteri in acute viral diarrhea.
Similar articles
-
Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis.Pediatr Infect Dis J. 1997 Dec;16(12):1103-7. doi: 10.1097/00006454-199712000-00002. Pediatr Infect Dis J. 1997. PMID: 9427453 Clinical Trial.
-
Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea.Pediatr Infect Dis J. 2002 May;21(5):411-6. doi: 10.1097/00006454-200205000-00012. Pediatr Infect Dis J. 2002. PMID: 12150178 Clinical Trial.
-
Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh.Pediatrics. 2005 Aug;116(2):e221-8. doi: 10.1542/peds.2004-2334. Epub 2005 Jul 1. Pediatrics. 2005. PMID: 15995003 Clinical Trial.
-
Probiotics for prevention and treatment of diarrhea.J Clin Gastroenterol. 2011 Nov;45 Suppl:S149-53. doi: 10.1097/MCG.0b013e3182257e98. J Clin Gastroenterol. 2011. PMID: 21992955 Review.
-
Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.J Pediatr Gastroenterol Nutr. 2001 Oct;33 Suppl 2:S17-25. doi: 10.1097/00005176-200110002-00004. J Pediatr Gastroenterol Nutr. 2001. PMID: 11698781 Review.
Cited by
-
Limosilactobacillus reuteri and Lacticaseibacillus rhamnosus GG differentially affect gut microbes and metabolites in mice with Treg deficiency.Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6):G969-G981. doi: 10.1152/ajpgi.00072.2021. Epub 2021 Mar 31. Am J Physiol Gastrointest Liver Physiol. 2021. PMID: 33787352 Free PMC article.
-
Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract.Appl Environ Microbiol. 2004 Feb;70(2):1176-81. doi: 10.1128/AEM.70.2.1176-1181.2004. Appl Environ Microbiol. 2004. PMID: 14766603 Free PMC article. Clinical Trial.
-
Rotavirus infection: a systemic illness?PLoS Med. 2007 Apr;4(4):e117. doi: 10.1371/journal.pmed.0040117. PLoS Med. 2007. PMID: 17439293 Free PMC article.
-
Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice.Infect Immun. 2011 Jan;79(1):185-91. doi: 10.1128/IAI.00880-10. Epub 2010 Oct 25. Infect Immun. 2011. PMID: 20974822 Free PMC article.
-
The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures.Pharmaceuticals (Basel). 2014 Sep 19;7(9):954-89. doi: 10.3390/ph7090954. Pharmaceuticals (Basel). 2014. PMID: 25244509 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources